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We have characterized a pathway for nuclear export of the glucocorticoid receptor (GR) in mammalian cells.
This pathway involves the Ca2 -binding protein calreticulin (CRT), which directly contacts the DNA binding
domain (DBD) of GR and facilitates its delivery from the nucleus to the cytoplasm. In the present study, we
investigated the role of Ca2 in CRT-dependent export of GR. We found that removal of Ca2 from CRT
inhibits its capacity to stimulate the nuclear export of GR in digitonin-permeabilized cells and that the
inhibition is due to the failure of Ca2-free CRT to bind the DBD. These effects are reversible, since DBD
binding and nuclear export can be restored by Ca2 addition. Depletion of intracellular Ca2 inhibits GR
export in intact cells under conditions that do not inhibit other nuclear transport pathways, suggesting that
there is a Ca2 requirement for GR export in vivo. We also found that the Ran GTPase is not required for GR
export. These data show that the nuclear export pathway used by steroid hormone receptors such as GR is
distinct from the Crm1 pathway. We suggest that signaling events that increase Ca2 could positively regulate
CRT and inhibit GR function through nuclear export.
The nuclear transport machinery integrates a variety of nu-
clear and cytoplasmic activities by mediating the translocation
of housekeeping and regulatory proteins and RNAs. Translo-
cation of these macromolecules generally requires a cis-acting
transport signal, recognition of the signal by a receptor, and
movement of the signal-receptor complex through the nuclear
pore complex (NPC) (40, 45). In the case of nuclear export,
most proteins rely on a hydrophobic nuclear export signal
(NES) and its recognition by the receptor Crm1 (1, 10, 11, 39,
44). NES binding to Crm1 is stabilized by the presence of
RanGTP, and the resulting trimeric complex of Crm1, NES,
and RanGTP undergoes translocation through the nuclear
pore (14, 28). Other proteins are important cofactors for this
export pathway, including RanGAP, RanBP1, NXT1, and
RanBP3 (1, 4, 22, 24).
A number of proteins that lack a hydrophobic NES are
known to undergo nuclear export, and current evidence indi-
cates that three distinct mechanisms can account for nuclear
export of these proteins. First, an NES-containing adapter
could be used to bridge the interaction between the protein
and Crm1 (21). Second, the protein could use a different signal
for nuclear export and undergo Crm1-independent export (3).
Third, the protein could interact directly with nucleoporins in
the NPC and undergo receptor-independent nuclear export
(46). An advantage of these mechanisms is that they provide
the potential for additional levels of regulation for protein
sorting between the nucleus and cytoplasm.
The glucocorticoid receptor (GR) is an example of a protein
that undergoes export from the nucleus even though it lacks a
hydrophobic NES. Moreover, GR export is insensitive to the
Crm1 inhibitor leptomycin B, which seems to rule out the use
of NES adapters and Crm1 as the major receptor for this
pathway (18, 25). The signal that specifies nuclear export of
GR maps to the 67-amino-acid DNA binding domain (DBD),
which is both sufficient to mediate the export of green fluores-
cent protein (GFP) reporter proteins and necessary for export
of GR (3). Mutations that disrupt DBD structure, whether in
the context of an isolated DBD or in full-length GR, also
reduce its export activity. The most severe mutations that re-
duce DBD-dependent nuclear export are two phenylalanine-
to-alanine mutations in the DNA recognition helix (3). The
structural conservation of the DBD in the nuclear receptor
superfamily suggests that the DBD could be widely used as an
export signal. Support for this hypothesis was obtained by
showing that the DBDs from steroid, nonsteroid, and orphan
nuclear receptors can function as export signals when fused to
a GFP reporter protein (3).
Nuclear export mediated by the DBD of GR involves a Ca2
binding protein named calreticulin (CRT), which was first de-
scribed as a protein in the lumen of the endoplasmic reticulim
(ER) (29). The original link between these proteins came with
the finding that a peptide sequence, KLGFFKR, which is rec-
ognized by CRT, is related to the peptide sequence KVFFKR,
which is found in the DNA recognition helix of GR (33). CRT
binds to GR and blocks its interaction with DNA in gel shift
experiments, and overexpression of CRT inhibits GR-depen-
dent transcription in cells (6). Similar results were obtained
when the interactions between the androgen, retinoic acid, and
vitamin D receptors and CRT were examined (8). The initial
interpretation of these results was that a pool of CRT outside
of the lumen of the ER acts as a negative regulator of tran-
scription. The technical difficulty of showing that CRT is out-
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side the ER, however, gave way to the view that CRT is re-
stricted to the ER lumen and that the effects of CRT on gene
expression are indirect (23).
Our laboratory purified CRT from HeLa cell cytosol in a
search for novel export factors (18). We used a permeabilized
cell assay that measures the nuclear export of protein kinase
inhibitor (PKI), a protein that contains a hydrophobic NES
(19). CRT can bind directly to the NES in PKI, which contains
the peptide sequence LALKLAGLDIN. In binding experi-
ments the interaction of CRT with PKI is stabilized in the
presence of RanGTP, and in permeabilized cells CRT-depen-
dent export of PKI is enhanced by RanGTP (18). The ability of
CRT to act as an export factor for PKI and its prior link with
steroid receptor function led us to test whether CRT can func-
tion as an export factor for GR. We found that recombinant
CRT can stimulate GR export and that the GR export defi-
ciency in crt/ cells can be rescued with CRT (18). These
observations support the view that CRT functions as an export
factor for GR.
In the present study we characterized the CRT-dependent
nuclear export of GR, with particular emphasis on how this
pathway could be regulated. Because CRT is a Ca2 binding
protein, we have examined how removing Ca2, either by che-
lation or by deletion of Ca2 binding domains, affects CRT
binding to the GR DBD and CRT-dependent nuclear export
of GR. We show that Ca2 binding to CRT is necessary for
direct binding to the DBD and for nuclear export of GR in
permeabilized cells. This Ca2 requirement involves the C-
terminal domain of CRT, which contains multiple low-affinity,
high-capacity binding sites for Ca2 (2). Removal of the C-
terminal domain renders CRT insensitive to Ca2 chelation,
suggesting that this domain performs a regulatory function that
is linked to Ca2 binding. While the Ca2-loaded CRT is
active for GR export and Ca2-free CRT is inactive for GR
export, the opposite is the case for NES export in permeabil-
ized cells. Thus, Ca2-loaded CRT is inactive for Rev export
and Ca2-free CRT is active for Rev export. The Ca2-loaded
and Ca2-free forms of CRT were shown to have different
sensitivities to proteases (7), indicating that CRT adopts dif-
ferent protein conformations. Our data show that these Ca2-
dependent conformations of CRT are correlated with the abil-
ity to recognize different protein substrates. Ca2 depletion in
vivo results in the inhibition of GR export, consistent with a
Ca2 requirement for the translocation of GR from the nu-
cleus to the cytoplasm. Our finding that CRT requires Ca2 for
binding and nuclear export of GR suggests a potential mech-
anism for regulating this pathway.
MATERIALS AND METHODS
Plasmids and recombinant proteins. Standard methods were used for the
expression and purification of glutathione S-transferase (GST)- and His-tagged
proteins, all of which were stored at 80°C as single-use aliquots. The plasmid
encoding the GST fusion with CRT was constructed in pGEX4T3, using the
open reading frame of mouse CRT lacking the N-terminal 17-amino-acid signal
sequence. GST-CRT was expressed in DH5 bacteria as described previously
(18). Full-length and deletion mutants of mouse CRT were cloned into pQE30,
and the His-tagged proteins were expressed in TG1 bacteria (3). The wild-type
(WT) and NES mutant forms of PKI (L41A, L44A) (44) were expressed in
BL21(DE3) bacteria and purified without fusion tags as described previously
(19). The plasmid encoding a hydrophobic NES was generated by cloning the
DNA sequence that encodes residues 35 to 49 of human PKI into pGEX4T3.
Likewise, the plasmid encoding a nuclear receptor DBD was generated by clon-
ing the DNA sequence that encodes residues 413 to 509 of human GR (3). The
GST-NES and GST-DBD proteins immobilized on glutathione beads were ei-
ther used directly for binding experiments or eluted and used in microtiter plate
binding assays. For certain competition experiments, WT and mutant (MUT)
forms of the GR DBD (FF to AA) were expressed as GST fusion proteins,
cleaved from GST using thrombin, and further purified by ion-exchange chro-
matography (3). Plasmids encoding His-tagged Ran (WT, Q69L, and T24N; a
gift of D. Go¨rlich) and His-tagged Crm1 (a gift of L. Gerace) were used to
express proteins in TG1 bacteria, which were purified on Talon resin (Clontech).
Binding assays. The three formats used for the solid-phase binding assays
were microtiter wells, biosensor cuvettes, and Sepharose beads. The microtiter
well assay was performed as described previously (4). Briefly, purified target
proteins were immobilized in high-binding 96-well plates (Costar no. 3590)
overnight at 4°C in 1 transport buffer (30). Unbound protein was removed, and
the plates were blocked overnight with bovine serum albumin (30 mg/ml). Bind-
ing assays (with 100-l mixtures) were performed in triplicate, using radiolabeled
Ran and CRT or Crm1, and the level of binding was measured by scintillation
counting as described previously (4). The biosensor assay was performed as
described previously (18). Briefly, biotinylated NES peptide was immobilized in
streptavidin-coated cuvettes (Fisons) for 15 min at room temperature. The cu-
vettes were washed with PBS and used for binding assays with the proteins
indicated in the legend to Fig. 3. A detailed description of the Fisons biosensor,
which measures the change in refractive index that occurs on protein-ligand
binding and dissociation, has been published (34). The Sepharose bead binding
assays, using either glutathione beads and GST proteins or Talon beads and
His-tagged proteins, were carried out by standard methods. Briefly, proteins
were immobilized on the beads and blocked overnight with bovine serum albu-
min (30 mg/ml), and the assays (with 100-l mixtures) were performed using the
proteins indicated in the legends. The bound fractions were examined by immu-
noblotting using antibodies to CRT or Crm1 and enhanced chemiluminescence.
Ca2 removal from CRT. Ca2 was removed from CRT by a published pro-
cedure that involves treatment with EGTA (43). Recombinant CRT (0.5 mg/ml
in PBS) was incubated for 10 min at 30°C in the presence of 10 mM EGTA, and
the sample was then transferred to ice. Ca2 was rebound to CRT by supple-
menting half of the EGTA-treated sample with excess CaCl2 (final Ca2 con-
centration, 20 mM). The EGTA- and Ca2-treated samples were used at a
dilution of at least 1:10 in nuclear export and binding assays, such that the
maximum concentration of EGTA in the assays was 1 mM.
GR export assays. Nuclear export of GR in permeabilized cells was performed
essentially as described previously (18), except that a stable cell line expressing
GR-GFP (a gift of G. Hager) was used instead of transiently transfected cells.
The cell line (3676 cells) (27) expresses GR-GFP under the control of a tetra-
cycline-regulated promoter. The cells were grown on glass coverslips for 16 h in
the absence of tetracycline to allow GR-GFP expression, and nuclear import of
GR-GFP was induced in vivo by dexamethasone (Dex; 1M) addition to the
media. The cells were permeabilized with digitonin (0.005%) for 5 min and used
for export assays in vitro with the combinations of transport factors indicated in
the legends. At the end of the 20-min export reaction, the samples were washed,
fixed, stained with 4,6-diamidino-2-phenylindole (DAPI), and mounted on glass
slides. Using a Nikon Microphot SA microscope (60 objective, numerical
aperture N.A.  1.40) and a Hamamatsu C-4742-95 charge-coupled device
camera, 50 nuclei from each coverslip were selected using the DAPI channel
and DAPI and GFP images were captured. The digital images were acquired
using Openlab 2.06 on a Macintosh G3 computer (OS 9.0), and figures were
assembled using Adobe Photoshop 5.5 and Freehand 9.0. Mixtures for reactions
that measured export and import in the same nuclei contained, in addition to
CRT or Crm1, the fluorescent protein allophycocyanin coupled with NLS pep-
tide (APC-NLS) and recombinant import factors (importins and NTF2).
Hydrophobic NES export assays. The assay for nuclear export of Rev in
permeabilized cells has been described previously (RGG2.2 cells) (18, 26). The
fluorescent reporter in this cell line (denoted Rev-GFP) also contains the ligand
binding domain of GR, which confers Dex-inducible import in vivo. Digitonin
permeabilization, nuclear export, and analysis using fluorescence microscopy
were performed as described above for GR-GFP. All export assay mixtures
contained Ran, NXT1, and RanBP1. In experiments designed to test the role of
Ran in CRT-dependent export, the T24N and Q69L mutant forms of Ran were
preloaded with unlabeled GDP and GTP, respectively, and unincorporated nu-
cleotide was removed on a desalting column.
Ca2 depletion in living cells. Nuclear export of GR was assayed under
conditions of Ca2 depletion in the 3676 cells by measuring the net redistribution
from the nucleus to the cytoplasm. Cells expressing GR-GFP were treated with
Dex for 1 h to induce nuclear import and subsequently transferred to phenol
red-free media containing ionomycin (Ion; 1 M) or thapsigargin (TG; 1 M) in
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the presence of 1,2-bis(O-aminophenoxy)ethane-N,N,N, N-tetraacetic acid-
acetoxymethyl ester (BAPTA-AM; 10 M). Cells were also treated with dimeth-
ylsulfoxide (DMSO; 0.1%) as a control since the Ion and TG were prepared as
1,000 stocks in DMSO. At 0-, 3-, and 6-h time points, the coverslips were fixed
in formaldehyde (3.7%) and mounted using Vectashield. The ratio of nuclear to
cytoplasmic GR-GFP fluorescence was measured using Openlab software in at
least 50 cells per condition. Similar methods were used to assay the effect of Ca2
depletion on Rev-GFP export using the RGG2.2 cells.
RESULTS
Assembly of CRT complexes in vitro. In digitonin-permeabi-
lized cells, CRT can stimulate the nuclear export of proteins
such as PKI that contain a hydrophobic NES, in a reaction that
is dependent on Ran (18). In addition, CRT can stimulate the
nuclear export of steroid hormone receptors that lack a hydro-
phobic NES. The export signal for CRT-dependent export of
steroid hormone receptors is contained within the DBD of
these proteins (3). The lack of apparent structural similarity
between the hydrophobic NES and the DBD led us to charac-
terize how CRT can recognize distinct export signals.
Because Ran is a stoichiometric component of export com-
plexes that contain Crm1 and NES proteins, we first examined
whether Ran might also function as a component of export com-
plexes that contain CRT. Previously, we have shown that Ran
assembles into a complex containing NES and CRT (18). In the
present study, we tested whether Ran can assemble into a com-
plex containing the DBD of GR (amino acids 413 to 509) and
CRT. WT PKI, NES MUT PKI, and GST-DBD were immobi-
lized in microtiter wells and incubated with recombinant CRT or
Crm1 (5 g each) in the presence of radiolabeled RanGTP (2 
104 cpm). RanGTP assembled into a complex with CRT or Crm1
in the presence of WT PKI. The reaction is specific since a
functional NES in PKI is required for complex assembly. In con-
trast to these results obtained with the NES-containing protein
PKI, RanGTP did not coassemble into a complex with CRT or
Crm1 in the presence of the DBD from GR (Fig. 1A). Thus, CRT
binding to the DBD is qualitatively different from CRT binding to
the hydrophobic NES, since only the latter involves RanGTP as a
stoichiometric component.
We carried out binding reactions with the DBD immobilized
on glutathione beads and confirmed that CRT binds directly to
the DBD and that binding is neither enhanced nor prevented by
RanGTP (Fig. 1B). Under the reaction conditions, Crm1 binding
to the hydrophobic NES was stimulated by the presence of
RanGTP (lane 6). We did not observe Crm1 binding to the DBD
in the absence or presence of RanGTP, consistent with our data
that Crm1 is not the receptor for proteins that use the DBD as an
export signal (18). Our data demonstrate that CRT can assemble
into two types of export complexes in vitro: a CRT-NES-RanGTP
complex and a CRT-DBD complex.
Ran-dependent and Ran-independent export by CRT. The
results of our binding assays suggested that CRT-mediated
export might occur by both Ran-independent and Ran-depen-
dent mechanisms. That is, the data suggested that nuclear
export of hydrophobic NES-containing proteins could be Ran
dependent and nuclear export of DBD-containing proteins
could be Ran independent. We tested this hypothesis by ma-
nipulating the composition and concentration of recombinant
export factors in permeabilized cell assays, using GFP fusions
of Rev and GR as the export substrates to assay NES- and
DBD-dependent export, respectively. Both GFP export sub-
strates contain the hormone binding domain of GR, which
directs efficient Dex-dependent nuclear import in vivo (31).
Following a digitonin permeabilization step, nuclear export of
the GFP reporters can be stimulated by the addition of soluble
transport factors (26).
We tested for the role of Ran in CRT-dependent NES
export by using Rev, which contains a hydrophobic NES (LP-
PLERLTL) (10). We used a concentration of CRT that was
determined to be subsaturating with respect to Rev-GFP ex-
port. In the presence of 0.2 M CRT, WT Ran preloaded with
GTP stimulated Rev-GFP export (Fig. 2A). In contrast, the
Ran mutant T24N, which mimics the GDP-bound form of Ran,
was inactive for CRT-dependent export. The Ran mutant
Q69L, which mimics the GTP-bound form of Ran, showed
little effect on export mediated by CRT, which is different from
FIG. 1. Formation of export complexes involving CRT and Crm1.
(A) The incorporation of RanGTP into complexes containing CRT
and Crm1 was assayed using Ran preloaded with [	-32P] GTP. Target
proteins were immobilized in microtiter wells (500 ng/well), and CRT
or Crm1 (5 g each) was added to each well together with 2 104 cpm
of radiolabeled RanGTP. Following incubation for 1 h at room tem-
perature, the wells were washed four times and the bound fractions
were released and assayed by scintillation counting. (B) RanGTP is not
a cofactor for CRT binding to the DBD. Target proteins (1 g each)
were immobilized on glutathione beads, and CRT or Crm1 (500 ng
each) was added to each sample in the absence or presence of Ran
(1 g) preloaded with cold GTP. The samples were mixed end over
end for 2 h at room temperature, washed three times, eluted, and
analyzed by immunoblotting with antibodies to CRT and Crm1. These
data show that, like Crm1, NES recognition by CRT involves RanGTP.
In contrast, DBD recognition by CRT does not involve RanGTP.
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previous results obtained using another RanGTP mutant
(G19V) and a fluorescent conjugate of PKI as the export sub-
strate (18). The reason for this discrepancy is unclear, but it
could relate to subtle differences in the structure and activity of
these mutant proteins or to the fact that different NES proteins
were used in the two assays, or both. Crm1 in these assays (Fig.
2B) supports robust export of Rev-GFP in the presence of WT
Ran preloaded with GTP. In the presence of the Ran mutant
Q69L, a moderate level of export was observed, while the Ran
mutant T24N failed to support Crm1-dependent export. Thus,
Ran stimulates both CRT- and Crm1-dependent export in this
system, and maximal export activity of either protein is ob-
served only in the presence of WT Ran.
GR-GFP export was assayed at the same concentration of
CRT (0.2 M) that, in the presence of RanGTP, promotes
efficient export of Rev GFP. We determined that the addition
of subsaturating CRT together with Ran does not support
nuclear export of GR. We also found that the addition of Crm1
FIG. 2. Ran is a cofactor for NES-dependent export but not for DBD-dependent export. Nuclear export was assayed by supplementing
digitonin-permeabilized cell assay mixtures with CRT (0.2 or 2.0 M), Crm1 (0.2 M), and different forms of Ran (1.9 M each). NES-dependent
export was assayed using a cell line that expresses a GFP fusion with Rev (RGG2.2) (26), and DBD-dependent export was assayed using a cell
line that expresses a GFP fusion with GR (3676) (27). The Rev-GFP fusion also contains the ligand binding domain of GR, which imparts
ligand-dependent nuclear import of the reporter protein. Prior to digitonin permeabilization, both cell lines were treated with Dex (1 M) to
induce nuclear import of the GFP reporters. (A and B) RanGTP stimulates Rev-GFP export in the presence of CRT or Crm1. (C and D) In
contrast, neither WT nor MUT forms of Ran stimulate GR-GFP export in the presence of CRT or Crm1.
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and RanGTP at concentrations (0.2 and 1.9 M, respectively)
that promote efficient Rev export fails to support GR export.
These transport data correlate with our in vitro binding data,
since CRT-dependent binding and export of an NES-contain-
ing protein is dependent on RanGTP. In contrast, CRT-de-
pendent binding and export of the DBD appears to be inde-
pendent of Ran. In the context of permeabilized cell assays,
CRT can substitute for Crm1 in the NES pathway; however,
Crm1 cannot substitute for CRT in the DBD pathway.
Overlapping export substrate binding sites on CRT. We
considered two models to account for the ability of CRT to
bind and mediate the nuclear export of two substrates with
apparently unrelated export signals. In the first model, CRT
could contain two distinct substrate binding sites, with only one
of the two sites regulated by RanGTP. In the second model,
CRT could contain a single substrate- binding site that accom-
modates both types of substrate and could use RanGTP to
regulate the binding of only one of the two types of substrate.
We reasoned that if CRT uses a single substrate binding site
(or a single type of binding site), then CRT binding to the
DBD should be inhibited in the presence of excess NES. To
address this issue, we assayed CRT binding to an immobilized
DBD in the absence and presence of WT and NES mutant
forms of PKI. CRT binding to the DBD was reduced by the
presence of WT PKI but not by the NES mutant form of PKI
(Fig. 3A). Our data are consistent with a single type of sub-
strate binding site on CRT, although we cannot rule out the
possibility that CRT contains a second substrate binding site
that is inhibited by an allosteric mechanism.
We also tested whether CRT contains a single type of sub-
strate binding site by assaying nuclear export in permeabilized
cells. Nuclear export of GR-GFP was tested in the absence and
presence of WT and NES mutant forms of PKI. Inclusion of
excess WT PKI (12 M) in the reaction mixture inhibited the
nuclear export of GR, whereas inclusion of the NES mutant
form of PKI at the same concentration had no effect (Fig. 3B).
GR export mediated by CRT was blocked by excess GR DBD
(4.5 M), consistent with previous data showing that the DBD
functions as the signal for nuclear export of GR (3, 18).
The assays described above (Fig. 3A and B) were designed
to measure the effect of excess NES on CRT binding to, and
export of, the DBD. We performed analogous protein binding
and nuclear export experiments that, instead, measured the
effect of excess DBD on the interaction between CRT and the
NES (Fig. 3C). In the biosensor assay, CRT binding to the
NES (green tracing) or Crm1 binding to the NES (purple
tracing) were both observed, but only in the presence of Ran
GTP. CRT binding to the NES was reduced markedly by the
presence of a WT DBD (light blue tracing), but this interaction
was unaffected by the presence of a MUT DBD (dark blue
tracing). The ability of the DBD to compete with NES for
binding to CRT provides evidence that a single type of binding
site is used for both substrates.
The effect of excess DBD on CRT-dependent export of NES
substrate was tested in permeabilized cells by using Rev-GFP
as a reporter. CRT-dependent export of Rev-GFP was inhib-
ited by excess DBD and, as expected, by excess WT PKI (Fig.
3D). Addition of excess WT PKI resulted in inhibition of
Crm1-dependent export of Rev-GFP, while addition of excess
DBD had no effect on Rev-GFP export (data not shown). In
summary, our results demonstrate that (i) CRT can bind to and
mediate the nuclear export of a protein that contains either a
hydrophobic NES or a steroid hormone receptor DBD, (ii)
CRT-dependent binding and export of a protein containing the
hydrophobic NES is dependent on Ran, (iii) CRT-dependent
binding and export of a protein containing an appropriate
DBD is not dependent on Ran, and (iv) CRT uses a similar
substrate binding site for proteins that contain either a hydro-
phobic NES or an appropriate DBD.
Ca2 is critical for CRT export activity. CRT was originally
discovered as a Ca2 binding protein (29), and many of its
functions in the ER have been proposed to be linked to its
ability to bind Ca2 (20). To determine if Ca2 influences the
nuclear export activity of CRT, we used an established method
to release Ca2 from recombinant CRT (43) and tested the
protein in binding and transport assays. EGTA-induced Ca2
release from CRT resulted in the loss of CRT binding to the
DBD. Binding to the DBD was, however, restored by the
addition of excess Ca2 (Fig. 4A). Ca2 removal from CRT
caused a corresponding reduction in its capacity to promote
nuclear export of GR in permeabilized cells, and the export
activity was restored by the addition of excess Ca2 (Fig. 4B).
Unexpectedly, the capacity of CRT to mediate nuclear export
of the NES substrate Rev-GFP was unaffected by EGTA, and
the addition of excess Ca2 to this assay actually inhibited
Rev-GFP export (Fig. 4C). The effect of Ca2 on Rev-GFP
export appears to be linked to CRT since these treatments did
not affect Crm1-dependent export of Rev-GFP (Fig. 4D).
These data suggest that the Ca2-bound state of CRT deter-
mines whether it binds to DBD- or NES-containing proteins
and that these interactions are mutually exclusive under the
conditions used in our assays.
We considered it formally possible that addition of EGTA to
digitonin-permeabilized cells could block GR export by inhib-
iting NPC function. Ca2 depletion in cells has been reported
to inhibit the nuclear import of an NLS reporter protein (15),
and there is structural evidence that depletion of Ca2 from
the lumen of the nuclear envelope can alter NPC structure
(41). It was also possible that Ca2-free CRT might accumu-
late at the NPC and block transit through the nuclear pore. We
addressed this issue in a permeabilized cell assay that recon-
stitutes both nuclear import and export (Fig. 5A), reasoning
that nuclear import would provide a relevant readout of NPC
activity that is independent of nuclear export. Import in these
assays was reconstituted by the addition of - and 
-importin,
Ran, and NTF2 and was monitored by the nuclear accumula-
tion of allophycocyanin conjugated with the simian virus 40
large T-antigen NLS (APC-NLS). EGTA effectively blocked
GR export without affecting APC-NLS import (Fig. 5B).
Moreover, excess Ca2 blocked CRT-dependent export of
Rev-GFP without affecting APC-NLS import. This effect was
specific to CRT since Crm1-dependent export of Rev-GFP was
unaffected by excess Ca2 (Fig. 5C). Our data are consistent
with Ca2-mediated regulation of the activity of CRT and not
with the inactivation of NPC function. We note that our stan-
dard assay buffer contains 1 mM EGTA. Because this condi-
tion is permissive for CRT-dependent export, removal of Ca2
from CRT may require the higher concentration of EGTA (10
mM) or pretreatment of purified CRT with EGTA at 30°C, or
both.
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The P-domain and C-terminal domain of CRT Impart Ca2
regulation. As diagrammed in Fig. 6A, the domain structure of
CRT includes an acidic C-terminal domain that contains mul-
tiple low-affinity, high-capacity Ca2 binding sites (KD  2
mM; 25 mol/mol) and a proline-rich P-domain that contains
high-affinity, low-capacity Ca2 binding sites (KD  1 M) (2).
In light of our data showing that Ca2 can regulate CRT-
dependent export of GR, we examined whether the C-terminal
FIG. 3. The DBD and hydrophobic NES use a common or overlapping binding site on CRT. (A) Binding assay with GST-DBD or GST (2 g
each) immobilized on glutathione beads and CRT (500 ng), RanGTP (2 g), and WT or MUT PKI (2 g) added in solution. The bound fractions
were analyzed by immunoblotting for CRT. Including WT PKI in the reaction reduced the level of CRT bound to the DBD, indicating that these
proteins bind to similar sites on CRT. This competition was not observed when RanGTP was omitted from the assay (data not shown), consistent
with Ran acting as a cofactor for NES binding but not for DBD binding. (B) Nuclear export of GR-GFP was assayed in permeabilized cells using
CRT (2.0 M) in the presence of buffer, excess DBD (4.5 M), or PKI (12 M WT or MUT). (C) Competitive binding interactions between NES,
DBD, and CRT measured in a biosensor assay. NES peptide was immobilized on the cuvette surface through a biotin-neutravidin linkage and was
used to measure the Ran-dependent binding of CRT in the absence and presence of DBD in the solution. The proteins used in the assay were
CRT (1.1 M), Crm1 (1.1 M), RanQ69L (1.9 M), and WT and MUT DBD from GR (9.1M each). CRT binds efficiently to NES peptide in
the presence of Ran (green tracing), and this can be competed with the WT DBD (light blue tracing) but not with the transport-defective MUT
DBD that contains the FF-to-AA mutations (dark blue tracing). Crm1 binding to the NES is unaffected by the presence of excess DBD (fuchsia
tracing). (D) The DBD competes with NES in the CRT-dependent export pathway. The cell line expressing Rev-GFP was used to assay export
in the presence of CRT (1.1 M), WT PKI (12 M), and WT DBD (9.1 M) as indicated.
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domain is required for CRT activity in our assays. CRT mu-
tants lacking a portion of the C-terminal domain (retaining
residues 1 to 350) or the entire C-terminal domain (retaining
residues 1 to 273) were still functional for nuclear export of
Rev-GFP, and the activities of these mutants was blocked by
excess Ca2 (Fig. 6B to D). From these data we infer that the
Ca2-dependent inhibition of hydrophobic NES export by
CRT can be ascribed to the high-affinity low-capacity Ca2
binding site in the P-domain.
The deletion mutants were also examined for the Ca2 de-
pendence of DBD binding and GR export. We found that the
deletion mutants still bound to the DBD in the presence of
Ca2 and that the mutant (residues 1 to 273) lacking the entire
C-terminal domain was able to bind to the DBD in the pres-
ence of EGTA, albeit to a lesser extent than was the full-length
CRT (Fig. 6E). This suggests that in the absence of Ca2, the
C-terminal domain normally exerts a negative regulation on
the substrate binding activity of CRT. Removal of the entire
C-terminal domain (residues 1 to 273) also resulted in loss of
the EGTA-dependent inhibition of GR export that is observed
with both the full-length and partial C-terminal domain dele-
tion mutant (Fig. 6F to H). These data indicate that the low-
affinity, high-capacity Ca2 binding sites in the C-terminal
domain of CRT are not required for nuclear export of hydro-
phobic NES or DBD-containing proteins but that they do
contribute a regulatory function. The Ca2 binding sites in the
C-terminal domain are important for the EGTA-sensitive GR
export, and the Ca2 binding site in the P-domain appears to
be sufficient to confer Ca2-induced inhibition of NES export.
GR-GFP Export is Sensitive to Ca2 Depletion. Our results
showing that GR undergoes CRT- and Ca2-sensitive export
in permeabilized cells prompted us to examine whether this
FIG. 4. Ca2 binding to CRT is necessary for nuclear export of GR. (A) Binding assay performed with GST-DBD or GST (2.5 g each)
immobilized on glutathione beads and CRT (500 ng). The amount of CRT bound in each reaction fraction was examined by immunoblotting for
CRT. The CRT used in the binding assay was untreated, pretreated with 10 mM EGTA, or pretreated with 10 mM EGTA and 20 mM CaCl2. Ca
2
removal from CRT inhibits binding to the DBD, and this can be reversed by addition of Ca2. (B and C) Ca2 is required for CRT-dependent
GR export; however, Ca2 inhibits CRT-dependent NES export. (D) The presence of excess EGTA and Ca2 in the permeabilized-cell assay
mixture does not affect the export mediated by Crm1. CRT and Crm1 were used at a final concentration of 1.1 M each in the export assays. The
pretreatment of CRT and Crm1 with EGTA is described in Materials and Methods.
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pathway is operational in living cells. The 3676 cell line (27),
which stably expresses GR-GFP, was treated with Dex to in-
duce import and then transferred to Dex-free medium that
contained reagents known to deplete luminal and cytosolic
Ca2. The effect of Ca2 depletion on nuclear export was
examined by fluorescence microscopy after 6 h and quantitated
by measuring the nuclear/cytoplasmic fluorescence ratio of
GR-GFP. The conditions included treatment with the Ca2
ionophore Ion (1 M) or the ER Ca2 pump inhibitor TG
(1 M). The membrane-permeable form of BAPTA-AM
(10 M) was included with Ion and TG to chelate Ca2 that
was released. We found that Ion or TG administered in the
presence of BAPTA-AM were both effective at blocking the
nuclear export of GR-GFP (Fig. 7A). During the export phase
of the experiment, the nuclear/cytoplasmic fluorescence in the
control cells showed a significant reduction from 11.9  2.1 to
1.5  1.5 (Fig. 7B). In contrast, the nuclear/cytoplasmic fluo-
rescence in the Ion- and TG-treated cells showed only a slight
reduction, to 9.9  1.2 and 10.5  0.9, respectively.
It is unlikely that Ion, TG, and BAPTA-AM cause a global
disruption of NPC structure because NES-dependent export of
Rev-GFP continues under Ca2 depletion conditions in vivo
(Fig. 7C) as well as in vitro (26). The transport of other cargos
is unaffected by Ca2 depletion in vivo, including Crm1-de-
pendent nuclear export of mitogen-activated protein kinase-
activated protein kinase 2 (42) and importin/karyopherin-de-
pendent nuclear import of Rev-GFP (B. Black, unpublished
observations). Our finding that nuclear export of GR in per-
meabilized cells is sensitive to the Ca2-bound state of the
CRT used in the assays suggests that depletion of Ca2 in vivo
blocks the CRT-dependent export of GR in the cell.
DISCUSSION
Our study has revealed that Ca2 and RanGTP can regulate
the nuclear export activity of CRT. Ca2 binding to CRT is
necessary for its interaction with the DBD of GR in solid-
phase binding assays and for nuclear export of GR in digitonin-
permeabilized cell assays. These interactions appear to be in-
dependent of Ran, since Ran is not required for CRT binding
to the DBD. Ran does not stimulate GR export when CRT is
rate-limiting in the assay, and GTPase-deficient mutants of
Ran do not block GR export. Under conditions where the
low-affinity Ca2 binding sites of CRT are saturated with Ca2,
CRT does not support the nuclear export of a hydrophobic
NES substrate. The export capacity for a hydrophobic NES
substrate can be restored by EGTA-mediated removal of Ca2
from CRT. Under these conditions of low Ca2, RanGTP acts
as a stimulatory factor of CRT in a mechanism that involves
the assembly of CRT, NES, and RanGTP into a complex (18).
Collectively, our data suggest that Ca2 binding determines
whether CRT interacts with DBD containing cargo or with
NES-containing cargo, and only the latter involves Ran.
The characterization of CRT over the past several years has
revealed that it can associate with structurally distinct sub-
strates (20). Studies of the chaperone-like functions of CRT
FIG. 5. Ca2 chelation with EGTA inhibits CRT-dependent export without affecting nuclear import in permeabilized cells. (A) Diagram
illustrating the assay for nuclear import (APC-NLS) and export (GR-GFP) in the same cells. (B) EGTA blocks CRT-dependent export of GR-GFP
without affecting the nuclear import of APC-NLS in the presence of 
-importin, Rch1, Ran, NTF2, NXT1, and RanBP1 (50g/ml each). (C) Excess
Ca2 blocks CRT-dependent export of Rev-GFP without affecting the nuclear import of APC-NLS.
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proposed to occur in the ER lumen have addressed the in vitro
interaction of CRT with oligosaccharides, both free in solution
and as a structural component of glycoproteins. CRT is capa-
ble of binding directly to high-mannose-containing oligosac-
charides, and CRT can partially suppress the aggregation of
certain glycosylated proteins exposed to elevated temperatures
(35). It can also suppress the thermal aggregation of nongly-
cosylated proteins (35). These data have been taken as evi-
FIG. 6. The low-affinity Ca2 binding sites in the C-terminal domain of CRT are not essential for nuclear export activity. (A) Diagram of the
CRT structure and sites of Ca2 binding. (B to D) Export assays performed with CRT proteins containing deletions in the low-affinity Ca2 binding
C-terminal domain. CRT lacking the entire C-terminal domain retains its Ca2-dependent inhibition of NES export, indicating that this is probably
due to the high-affinity, low-capacity Ca2 binding site. (E) EGTA-sensitive binding of CRT to the DBD is partially lost on removal of the
C-terminal domain (residues 1 to 273). (F to H) Removal of the entire C-terminal domain (residues 1 to 273) from CRT abrogates the EGTA-
sensitive export of GR. Although the C-terminal domain of CRT is not required for export, it is necessary for Ca2 regulation of GR export.
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dence that in the ER, CRT may use both its lectin and peptide
binding properties to stabilize protein-folding intermediates.
The view that CRT participates in the folding of glycoproteins
in the ER is logical, given the sequence relatedness (34%
identity; expectation value, 1050) and functional similarities
to the ER chaperone calnexin. Calnexin is a key component of
a quality control pathway that monitors the folding state of
glycoproteins in the ER. The current view is that calnexin and
CRT interact transiently with protein-folding intermediates,
effectively retaining them in the ER until a native conforma-
tion is attained (17).
Studies of the functions of CRT that occur outside the ER
have yielded an even more diverse collection of substrates (20).
These include the cytoplasmic domain of -integrins (33), ste-
roid hormone receptors (6), NES-containing proteins (18), and
a stem-loop structure from rubella virus RNA (38). Some of
these substrates contain a binding site for CRT that can be
recognized at the sequence level, while other substrates seem
structurally distinct. The site within -integrin recognized by
CRT is the sequence KXGFFKR, which is similar to the se-
quence KVFFKR within the DNA recognition helix of GR and
other nuclear receptors. The NESs in PKI (LALKLAGLDIN)
and Rev (LPPLERLTL) are similar to each other, but they
show little resemblance to the CRT binding sites in -integrin
and the DNA recognition helix. One feature that is shared by
most of these signals is the presence of hydrophobic amino
acids that, when mutated, abrogates binding to CRT. In the
case of the hydrophobic NES, the critical leucines are probably
part of an amphipathic helix and the side chains are predicted
to physically contact the receptors Crm1 and CRT. This is not
the case for the two phenylalanines within the DNA recogni-
tion helix that are necessary for binding to CRT (3). The
crystal structures of different nuclear receptors reveal that the
phenylalanine side chains pack against the core of the DBD, at
least when bound to DNA (32). Thus, the FF-to-AA mutations
in the DNA recognition helix of GR that inhibit nuclear export
probably affect the folding of the DBD, resulting in a structure
that is no longer recognized by CRT (3).
How does CRT recognize its substrates? Our present study
and previous work from other laboratories suggest that the
N-terminal domain mediates substrate recognition and that
regulation of binding is imparted by the Ca2-dependent con-
formational changes in the P-domain and C-terminal domain
of CRT. Multiple low-affinity Ca2 binding sites are contained
within the C-terminal domain of CRT, and at least one high-
affinity Ca2 binding site is contained in the middle domain
(P-domain) (2). Ca2 is a cofactor for CRT binding to oligo-
saccharides, glycoproteins, and certain nonglycosylated pro-
teins in vitro (43). Moreover, in our assays, Ca2 is necessary
for the physical interaction between CRT and the DBD as
FIG. 7. Ca2 depletion in vivo inhibits the nuclear export of GR.
(A) Representative fields of cells expressing GR-GFP after induction
of nuclear import with Dex (Import). Following Dex removal, the cells
were treated for 5 h with vehicle (DMSO), Ion and BAPTA-AM, or
TG and BAPTA-AM, and the GR-GFP distribution was recorded in
living cells. (B) Measurements of the nuclear/cytoplasmic (Nuc/Cyto)
ratios of GR-GFP fluorescence in cells incubated under conditions
that deplete Ca2. Depletion of luminal stores of Ca2 with Ion and
TG and chelation with BAPTA-AM results in significant reduction of
GR export to the cytoplasm. (C) Depletion of luminal Ca2 stores
does not inhibit NES export. The RGG 2.2 cell line expressing Rev-
GFP was treated with Dex to induce importing of the reporter, which
concentrates in the nucleoli. The cells were then maintained for 6 h
under conditions that deplete Ca2. During the last 1 h, Dex was
removed to allow Rev-GFP export to the cytoplasm. Rev-GFP export
was observed whether or not Ca2 was depleted.
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measured by direct binding and as assayed by nuclear export of
GR in permeabilized cells.
Ca2 binding induces structural changes in CRT that dra-
matically alter its fragmentation pattern that results when it is
treated with several different proteases (7). Of particular rel-
evance to our study is the N-terminal 27 kDa of CRT, which is
protected from tryptic digestion in the presence of Ca2 but is
highly susceptible in the absence of Ca2 (7). This protease-
resistant core of CRT retains at least one high-affinity Ca2
binding site from the P-domain, while all of the low-affinity
Ca2 binding sites in the C-terminal domain are removed by
digestion. We found that a CRT deletion mutant (residues 1 to
273) that contains the protease-resistant core is still functional
for nuclear export of GR in permeabilized cells, indicating that
the low-affinity Ca2 binding sites are dispensable for our
assays that score a positive interaction between CRT and GR.
It is interesting that this CRT deletion mutant (residues 1 to
273) shows some Ca2-independent binding to the DBD, al-
though the high-affinity Ca2 binding site is still present in this
mutant. The fact that the C-terminal Ca2 binding sites are
necessary for EGTA-induced inhibition of CRT binding to the
DBD strongly suggests that the C-terminal domain functions in
negative regulation of substrate binding. We have also ob-
served that the N-terminal domain of CRT (residues 1 to 150)
expressed as a GST fusion protein is sufficient to mediate
nuclear export of GR in permeabilized cells (unpublished ob-
servations). This is consistent with previous data showing that
the N-terminal domain of CRT can block GR binding to the
GRE in vitro (6). All available information indicates, there-
fore, that the N-terminal domain of CRT is the substrate
binding domain that physically contacts the DBD of GR. We
infer that the N-terminal domain also binds hydrophobic NES
substrates, since the DBD and NES display competitive inter-
actions with CRT in our binding assays.
Emerging structural information provides a context for in-
terpreting how Ca2 might regulate CRT activity. Although
the atomic structure of CRT has not yet been solved, the
structure of the luminal domain of calnexin, which is 35%
identical to CRT, has been solved at 2.9 A˚ resolution (37). The
structure of calnexin reveals that it contains a compact globular
domain (residues 61 to 262 and 415 to 458) and a large hairpin
that forms a highly extended arm (residues 277 to 410). Tan-
dem repeats in the P-domain comprise the arm, which projects
140 A˚ away from globular domain. The hairpin structure brings
the N- and C-terminal domains together to form the globular
domain (37). Thus, the close proximity of these domains may
help explain how the occupancy of Ca2 binding sites in the
C-terminal domain can influence substrate recognition by the
N-terminal domain in both calnexin and CRT. The nuclear
magnetic resonance spectroscopy structure of the P-domain of
CRT (residues 189 to 288) was recently solved, and, like cal-
nexin, this domain forms a highly extended arm (9). The crystal
structure of calnexin and the nuclear magnetic resonance spec-
troscopy structure of the P-domain of CRT were both solved in
the presence of Ca2, and so the basis of Ca2-dependent
changes in structure awaits further studies. It has been sug-
gested that the P-domain or arm is a Ca2-sensitive protein
interaction site for CRT (9).
Does Ca2 regulate the engagement of CRT with nuclear
export substrates? Both cytoplasmic and nuclear Ca2 levels
can respond to signaling events, and in some cases the modu-
lation of nuclear Ca2 occurs independently of cytoplasmic
Ca2 (36). Depending on the system and method of measure-
ment, Ca2 levels in the cell are thought to increase to approx-
imately micromolar concentrations on stimulation (5). This
concentration would be predicted to fill the high-affinity Ca2
binding sites on CRT but not the low-affinity sites. It should be
noted, however, that the affinity of CRT for Ca2 was mea-
sured in vitro. While it is clear that CRT contains at least two
classes of binding sites with different affinities for Ca2, dem-
onstrating the Ca2 occupancy of particular sites on CRT in
the cell may require the development of fluorescence-based
assays that can register Ca2 binding. This approach could be
used to determine if Ca2 is constitutively bound to CRT or
if Ca2 binds reversibly, thereby acting as a regulator of
CRT function. We speculate that transient increases in Ca2
concentration, theoretically, could promote the assembly of
CRT-DBD complexes in the nucleus. The complex could then
undergo export to the cytoplasm, where the complex is disas-
sembled, which would be favored by low free Ca2 concentra-
tions.
Although the origin of nuclear Ca2 remains an issue of
debate, it is clear that processes including transcription are
regulated by nuclear Ca2 (16). Several observations are ac-
tually consistent with the notion that Ca2 gradients between
the nucleus and cytoplasm might be used to promote the as-
sembly and disassembly of CRT complexes. First, the presence
of Ca2 ATPases in the nuclear envelope and the lack of Ca2
buffering and sequestration proteins in the nucleus should pro-
long the availability of free Ca2 (12). Second, the inner mem-
brane of the nuclear envelope contains both major Ca2 re-
lease channels, which may be activated independently of
channels in the ER membrane that face the cytoplasm (36).
Third, morphological data show that the ER forms invagina-
tions that reach deep into the nucleus (13), which could place
Ca2 release channels close to sites of CRT-DBD assembly in
the nucleoplasm. While it is clear that Ca2 levels in the
nucleus do change in response to signaling events, it remains to
be established whether Ca2 regulation of CRT is a dynamic
process that involves reversible binding or whether Ca2 is
constitutively bound and simply maintains the tertiary struc-
ture of CRT.
CRT is thought to function in multiple pathways in the cell
(23). In the ER, CRT may function as (i) a chaperone that
mediates folding by transiently binding to oligosaccharide side
chains and peptide domains, (ii) a Ca2 storage protein in-
volved in Ca2 homeostasis, and (iii) a factor that directly
regulates the activity of the Ca2 pumps. At the plasma mem-
brane, CRT may modulate (i) cell migration by interacting
with adhesion plaque proteins and (ii) cell-cell interactions by
interacting with cell surface proteins. In the nucleocytoplasmic
compartment, CRT can regulate (i) the activity of steroid re-
ceptors through direct binding to the DBD of these proteins
and (ii) the redistribution of steroid receptors to the cytoplasm.
Because most of these functions mentioned above have been
linked to the Ca2 binding activity of CRT, conditions that
influence the Ca2 levels are predicted to regulate the activity
of CRT. In this regard, our findings that Ca2 is necessary for
the nuclear export function of CRT in vitro and that Ca2
depletion results in GR export defects in vivo suggest that this
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pathway is used to regulate the nucleocytoplasmic distribution
of GR and possibly other steroid hormone receptors. This link
between Ca2 and GR export could negatively regulate tran-
scription through a nuclear transport pathway, perhaps using
Ca2 as a second messenger.
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